Integrum AB - Class B INTEG B

STO: INTEG B | ISIN: SE0009807266   23/05/2025
18,50 SEK (+10,25%)
(+10,25%)   23/05/2025

5 mei 2025 · Integrum appoints Martin Hillsten as new Chief Executive Officer · Persbericht

28 maart 2025 · Integrum implements new compensation package for its CEO · Persbericht

18 maart 2025 · Integrum's OPRA™ Implant System demonstrates superior treatment outcomes in two-year follow-up study by Walter Reed National Military Medical Center · Persbericht

29 februari 2024 · CORRECTION: Integrum AB: A new record revenue quarter with 61% growth · Persbericht

29 februari 2024 · Integrum AB: A new record revenue quarter with 61% growth · Persbericht

23 februari 2024 · Integrum AB: Invitation to the Third Quarter 2023/24 Results Presentation · Persbericht

1 februari 2024 · Integrum has sold and delivered OPRA™ Implant Systems to a value of SEK 3.5 million to Center of Excellence in Ukraine · Persbericht

20 december 2023 · Integrum establishes Center of Excellence in Ukraine · Persbericht

4 december 2023 · Record sales and profitability: Integrum AB · Persbericht

13 november 2023 · Integrum plans to submit a PMA application to the FDA for the use of OPRA in transhumeral amputations based on existing clinical data · Persbericht

10 november 2023 · Correction missing MAR reference: Integrum publishes preliminary revenue, result and and cash flow figures for Q2, 2023 · Persbericht

10 november 2023 · Clinical study of Integrum's OPRA™ Implant System on below-knee amputations will include up to 30 patients and is fully funded by the Department of Defense · Persbericht

9 november 2023 · Integrum publishes preliminary revenue, result and and cash flow figures for Q2, 2023 · Persbericht

30 oktober 2023 · Integrum's OPRA™ Implant System gets FDA approval for clinical study on below-knee amputations · Persbericht

27 oktober 2023 · Integrum moves into Turkey · Persbericht

Mijn selecties